Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative radiotherapy with or without concurrent cisplatin and 5-fluorouracil for advanced oesophageal cancer
ACTRN12606000526572Phase 3Completed
- Sponsor
- Trans-Tasman Radiation Oncology Group
- Start
- Jul 2003
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of cisplatin and fluorouracil in esophageal cancer (2 arms), sponsored by Trans-Tasman Radiation Oncology Group. Primary endpoint: Relief of dysphagia. Started Jul 2003; status: completed.
02
Drugs
cisplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ACTRN12606000526572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000526572.